Evidence map›Paper›PMID 38927455›Full record

ReviewBiomedicines2024

The Impact of COVID-19 on the Guillain-Barré Syndrome Incidence.

Magdalena Kopańko, Magdalena Zabłudowska, Monika Zajkowska, Monika Gudowska-Sawczuk, Mateusz Mucha, Barbara Mroczko

Abstract readReview
In one paragraph

Review in Biomedicines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Magdalena KopańkoDepartment of Biochemical Diagnostics, Medical University of Bialystok, 15-269 Bialystok, Poland.
Magdalena ZabłudowskaDepartment of Biochemical Diagnostics, Medical University of Bialystok, 15-269 Bialystok, Poland.
Monika ZajkowskaDepartment of Neurodegeneration Diagnostics, Medical University of Bialystok, 15-269 Bialystok, Poland.ORCID 0000-0002-5179-0722
Monika Gudowska-SawczukDepartment of Biochemical Diagnostics, Medical University of Bialystok, 15-269 Bialystok, Poland.ORCID 0000-0003-4854-7155
Mateusz MuchaDepartment of Oncological Surgery with Specialized Cancer Treatment Units, Maria Sklodowska-Curie Oncology Center, 15-027 Bialystok, Poland.
Barbara MroczkoDepartment of Biochemical Diagnostics, Medical University of Bialystok, 15-269 Bialystok, Poland.ORCID 0000-0002-4075-8479

Funding

Medical University of Białystok B.SUB.24.517
6 · The paper itself

Abstract

Despite the fact that the global COVID-19 pandemic has officially ended, we continue to feel its effects and discover new correlations between SARS-CoV-2 infection and changes in the organism that have occurred in patients. It has been shown that the disease can be associated with a variety of complications, including disorders of the nervous system such as a characteristic loss of smell and taste, as well as less commonly reported incidents such as cranial polyneuropathy or neuromuscular disorders. Nervous system diseases that are suspected to be related to COVID-19 include Guillain-Barré syndrome, which is frequently caused by viruses. During the course of the disease, autoimmunity destroys peripheral nerves, which despite its rare occurrence, can lead to serious consequences, such as symmetrical muscle weakness and deep reflexes, or even their complete abolition. Since the beginning of the pandemic, case reports suggesting a relationship between these two disease entities have been published, and in some countries, the increasing number of Guillain-Barré syndrome cases have also been reported. This suggests that previous contact with SARS-CoV-2 may have had an impact on their occurrence. This article is a review and summary of the literature that raises awareness of the neurological symptoms' prevalence, including Guillain-Barré syndrome, which may be impacted by the commonly occurring COVID-19 disease or vaccination against it. The aim of this review was to better understand the mechanisms of the virus's action on the nervous system, allowing for better detection and the prevention of its complications.

Indexed as

COVID-19Guillain–Barré syndromeneurological disorderSARS-CoV-2viral infection

Identifiers

PMID38927455
PMCPMC11201746

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.